{"id":7177,"date":"2025-05-01T11:08:47","date_gmt":"2025-05-01T16:08:47","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=6026"},"modified":"2025-07-13T15:09:16","modified_gmt":"2025-07-13T20:09:16","slug":"nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/","title":{"rendered":"El Dr. Subrata Batabyal, Director de Desarrollo No Cl\u00ednico de Nanoscope, es reconocido por su labor pionera en la restauraci\u00f3n de la visi\u00f3n mediante optogen\u00e9tica."},"content":{"rendered":"
\n
\n
\n
\n
\n

<\/h1>\n

Batabyal recibe el Premio Carl Camras de Investigaci\u00f3n Traslacional 2025 de la Fundaci\u00f3n ARVO.<\/em><\/h3>\n

\u00a0<\/p>\n<\/div>\n

\n
\n

DALLAS, 1 de mayo de 2025 \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con la restauraci\u00f3n de la visi\u00f3n en pacientes ciegos en entornos reales mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias g\u00e9nicas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que el Dr. Subrata Batabyal, Director de Desarrollo No Cl\u00ednico, ha recibido Premio Carl Camras 2025 de Investigaci\u00f3n Traslacional de la Fundaci\u00f3n ARVO<\/a> por su labor pionera en la restauraci\u00f3n de la visi\u00f3n mediante optogen\u00e9tica.<\/p>\n

El premio, dotado con 12.000 libras esterlinas, reconoce a investigadores noveles dedicados a la investigaci\u00f3n traslacional. El Dr. Batabyal contribuy\u00f3 significativamente a la traslaci\u00f3n de la opsina multicaracter\u00edstica (MCO-010), una innovadora terapia g\u00e9nica que utiliza prote\u00ednas fotosensibles para restaurar la visi\u00f3n en pacientes con enfermedades retinianas hereditarias. La terapia ha progresado con \u00e9xito desde los estudios de laboratorio hasta los ensayos cl\u00ednicos., demostrando resultados prometedores en el tratamiento de pacientes con retinosis pigmentaria<\/a> y otros trastornos retinianos hereditarios. El Dr. Batabyal recibir\u00e1 el premio durante La Asociaci\u00f3n para la Investigaci\u00f3n y la Visi\u00f3n en Oftalmolog\u00eda (ARVO) 2025<\/a>\u00a0Reuni\u00f3n anual, que se celebrar\u00e1 en Salt Lake City del 4 al 8 de mayo.<\/p>\n

Los detalles de la recepci\u00f3n de entrega de premios de la Fundaci\u00f3n ARVO son los siguientes:<\/p>\n

Fecha: Domingo, 4 de mayo de 2025
\nHorario: 11:45 a. m. \u2013 1:00 p. m. (hora de la monta\u00f1a)
\nUbicaci\u00f3n: Centro de Convenciones Calvin L. Rampton Salt Palace, Sala 155EF<\/p>\n

\u201cEl Dr. Batabyal sigue liderando iniciativas de investigaci\u00f3n pioneras en la restauraci\u00f3n de la visi\u00f3n en Nanoscope\u201d, declar\u00f3 el Dr. Samarendra Mohanty, cofundador y presidente de Nanoscope. \u201cEs un claro ejemplo del extraordinario equipo que hemos formado, el cual est\u00e1 desarrollando tratamientos de restauraci\u00f3n de la visi\u00f3n de \u00faltima generaci\u00f3n que podr\u00edan beneficiar a millones de pacientes en todo el mundo que actualmente cuentan con opciones de tratamiento limitadas\u201d.\u201d<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que actualmente no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan para iniciar en 2025 un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>. La compa\u00f1\u00eda ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 la designaci\u00f3n de v\u00eda r\u00e1pida de la FDA y la designaci\u00f3n de medicamento hu\u00e9rfano de la FDA para RP y Stargardt. Los programas precl\u00ednicos incluyen un f\u00e1rmaco MCO-020 no viral, administrado por l\u00e1ser y listo para la solicitud de nuevo f\u00e1rmaco en investigaci\u00f3n (IND) para la atrofia geogr\u00e1fica (GA), as\u00ed como un f\u00e1rmaco AAV para la amaurosis cong\u00e9nita de Leber, en estudios precl\u00ednicos.<\/p>\n

Contacto de inversores:<\/strong>
\nSocios Argot
\n212-600-1902
\nPR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Batabyal receives 2025 Carl Camras Translational Research Award from ARVO Foundation \u00a0 DALLAS,\u00a0May 1, 2025\u00a0\u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Dr. Subrata Batabyal, Director of Nonclinical Development, has received 2025 Carl […]<\/p>\n","protected":false},"author":6,"featured_media":7180,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-7177","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-01T16:08:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:09:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration\",\"datePublished\":\"2025-05-01T16:08:47+00:00\",\"dateModified\":\"2025-07-13T20:09:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_LI_SubrataAward_V1_REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/\",\"name\":\"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_LI_SubrataAward_V1_REV.jpg\",\"datePublished\":\"2025-05-01T16:08:47+00:00\",\"dateModified\":\"2025-07-13T20:09:16+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_LI_SubrataAward_V1_REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_LI_SubrataAward_V1_REV.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/05\\\/01\\\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El Dr. Subrata Batabyal, Director de Desarrollo No Cl\u00ednico de Nanoscope, es reconocido por su labor pionera en la restauraci\u00f3n de la visi\u00f3n mediante optogen\u00e9tica - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-05-01T16:08:47+00:00","article_modified_time":"2025-07-13T20:09:16+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration","datePublished":"2025-05-01T16:08:47+00:00","dateModified":"2025-07-13T20:09:16+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/"},"wordCount":399,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_LI_SubrataAward_V1_REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/","url":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/","name":"El Dr. Subrata Batabyal, Director de Desarrollo No Cl\u00ednico de Nanoscope, es reconocido por su labor pionera en la restauraci\u00f3n de la visi\u00f3n mediante optogen\u00e9tica - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_LI_SubrataAward_V1_REV.jpg","datePublished":"2025-05-01T16:08:47+00:00","dateModified":"2025-07-13T20:09:16+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_LI_SubrataAward_V1_REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_LI_SubrataAward_V1_REV.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/05\/01\/nanoscope-director-of-nonclinical-development-dr-subrata-batabyal-recognized-for-pioneering-work-in-optogenetic-vision-restoration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=7177"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7177\/revisions"}],"predecessor-version":[{"id":7211,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7177\/revisions\/7211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/7180"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=7177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=7177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=7177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}